SCHEMBL3101663

SCHEMBL3101663

Cc1oc(-c2cnn(C)c2)cc1C(O)CC(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.35
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
GRN P28799 1/20 0.34
SORT1 Q99523 1/20 0.34
KDM4E B2RXH2 2/20 0.33
FYN P06241 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
PKM P14618 1/20 0.33
PIM1 P11309 1/20 0.33
PIM2 Q9P1W9 1/20 0.33
KCNJ1 P48048 1/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
MAP3K7 O43318 1/20 0.32
TAB1 Q15750 1/20 0.32
GSK3B P49841 1/20 0.32
DYRK1A Q13627 1/20 0.32
PDK2 Q15119 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3095936 0.85 HSP90AA1 (0.33) AAK1HSP90AA1HSP90AB1GRNSORT1
SCHEMBL3106845 0.78 IDO1 (0.46) MAP3K7TAB1GSK3BBRD4JAK2
SCHEMBL3095057 0.75 ALDH1A1 (0.39) KDM4EALDH1A1LMNAPOLBCA12
SCHEMBL3101751 0.75 AAK1 (0.40) AAK1HSP90AA1HSP90AB1GRNSORT1
SCHEMBL3106494 0.74 DYRK1A (0.32) DYRK1AMKNK1MKNK2CA12CA1
SCHEMBL3107077 0.73 NPC1 (0.33) KCNH2CA12CA1CA2CA3
SCHEMBL3102659 0.73 NPC1 (0.48) KDM4EALDH1A1PKMPOLBCA12
SCHEMBL3099760 0.72 HDAC6 (0.41) PIK3CAMKNK1MKNK2KCNH2JAK2
SCHEMBL3106856 0.71 HPGD (0.47) KDM4EALDH1A1LMNAKCNH2POLB
SCHEMBL3099454 0.71 AAK1 (0.37) AAK1MKNK1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR AAK1 3786/4885HSP90AA1 3148/4885HSP90AB1 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.